Leadership Team

The BioSymetrics leadership team possesses significant expertise and professional experience in data science, medicine, and healthcare technology. Our solutions are underpinned by cross-disciplinary capabilities in machine learning, predictive analytics, big data, bioinformatics, computational biology, advanced image processing, and health IT.

Gabriel Musso, PhD

Chief Scientific Officer, Gabe@BioSymetrics.com
As CSO and head of Life Sciences, Gabe is expanding BioSymetrics’ scientific leadership in our key healthcare and biomedical markets for our Augusta™ platform, in areas such as biopharma R&D informatics, precision medicine, drug compound HTL generation, genomics, imaging and clinical diagnosis. Previously, Gabe was an Associate Scientist at Brigham and Women’s Hospital where his work focused on using machine learning frameworks to predict gene and small molecule function, and identification of disease-causal genes using large-scale genomic datasets. Gabe received his Ph.D. in Molecular Genetics from the University of Toronto. He also received his Masters of Science and undergraduate degrees from the University of Toronto.

Babak Afshin-Pour, PhD

VP Technology, Babak@BioSymetrics.com
As VP of Technology, Babak is a founding member of our engineering team, and leads technical development and product architecture of BioSymetrics’ machine learning platform. He has expertise in big data analytics, biomedicine, advanced medical signal and image processing, evaluation and optimizing of fMRI analysis techniques, graph theoretical network analysis, and analysis of multi-site neuroimaging data. His proposed analysis frameworks have been published in leading journals such as HBM, NeuroImage, and TMI. Babak received a B.S. in biomedical engineering as well as his M.S. and Ph.D. in electrical engineering from the University of Tehran with distinction. After earning his Ph.D., he completed a post-doctoral fellowship at Rotman Research Institute, University of Toronto.

Victoria Catterson, PhD

Principal Data Scientist, Victoria@BioSymetrics.com
Victoria is a Data Scientist with 14 years of experience in building and delivering machine learning solutions. She has worked on all aspects of the data science pipeline, from data cleansing and dimensionality reduction, to developing predictive and diagnostic models. She received the BEng (Hons) 1st class in computer and electronic systems, and the Ph.D. in electrical engineering with a focus on techniques for integrating diagnoses from multiple machine learning models. Previously she was a tenured Senior Lecturer at University of Strathclyde in Glasgow, Scotland. She has published over 20 peer reviewed journal articles, and is a Senior Member of the Institute of Electrical and Electronic Engineers. She has shown a longstanding commitment to science and engineering outreach, by working with school children to develop mobile apps and running machine learning workshops for Women Who Code Toronto.

James Hornblower

Business Development Director, James@BioSymetrics.com
With over 25 years of experience working with senior executives in pharma, biotech, and medical device companies, James Hornblower specializes in identifying/tailoring best-in-class SaaS based solutions that align with specific C-level strategic goals.  James’ broad experience working with Global Strategic Commercial Operations, Directors of Business Intelligence, Market Research and Competitive Intelligence, Research and Development, and Advanced Data Analytics, enables him to create targeted strategies to help clients achieve actionable insights for their patients and businesses, by comparing multiple data sources that leverage pre-processing of data, artificial intelligence (AI), and machine learning (ML).

Brian Stoller

Marketing, Brian@BioSymetrics.com

Brian Stoller has over 25 years of marketing experience building brands and managing performance driven campaigns. He is fluent in Mandarin Chinese and has global experience, leading marketing and branding teams across Asia and North America.  He spent 6 years as Executive Director of Marketing at IBM, where he oversaw the media strategies for IBM software including Watson Health. Prior to that he has experience with Maddison Avenue ad agencies and has built a successful start-up brand, sold to AOL in 2007.

Strategic Advisory Board

Dr. Calum MacRae, MD, PhD

Dr. MacRae is the Vice Chair for Scientific Innovation at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, and co-chair of BWH’s Genomic Medicine Program. Dr. MacRae’s lab at BWH is focused on understanding the mechanisms of cardiovascular disease and their therapy using human studies and complementary high-throughput biology in the zebrafish. As a member of the Harvard Stem Cell Institute, Dr. MacRae’s interests include the role of functional inputs, such as mechanical or electrical forces, in refining cardiovascular development. He is also the leader of the “One Brave Idea” project to fight coronary heart disease, a $75 million initiative funded by the American Heart Association, Verily, and Astra Zeneca.

Paul Boutros, MBA PhD

Paul Boutros is a Principal Investigator at the Ontario Institute for Cancer Research (OICR), and Associate Professor in the Departments of Pharmacology and Toxicology, and Medical Biophysics at the University of Toronto. Dr. Boutros also serves as the co-lead of the Canadian Prostate Cancer Genome Network (CPC-GENE) and has led somatic mutation calling challenges for the worldwide bioinformatics community. Dr. Boutros’ laboratory uses genome-scale datasets to identify patient specific cancer biomarkers, allowing application of personalized therapeutics for all cancer types, although specifically focused on prostate cancer. His research focuses on novel methods for integrating predictive analytics, outcomes, and molecular biology into new diagnostic applications and oncology R&D advances.

Gene Salkind, MD

Gene Salkind, currently serves as Chairman of Neurosurgery at Holy Redeemer Hospital in Pennsylvania. Dr. Salkind has practiced neurosurgery in the Philadelphia area for over 30 years, and previously served as Chairman of Neurosurgery at the Albert Einstein Medical Center. He has been a Director of DermTech International since May 2007 and serves on several other boards, including the SAB for Cure Pharmaceuticals. Dr. Salkind has published multiple papers and held professorships at leading teaching hospitals including the University of Pennsylvania Medical School.

Chinnappa Kodira, MS

Chinnappa Kodira, MS is the Managing Partner for an advanced analytics consultancy that serves life sciences and healthcare organizations. Most recently he served as Head of Computational Modeling, and Bioinformatics Strategy Leader at GE Global Research where he led the efforts on developing integrated data analytic solutions using omics, pathology, imaging and clinical data for accurate patient stratification, disease scoring and network modeling for research applications in oncology, immunology and neurodegenerative diseases. Prior to GE, his work included building first-in-class R&D applications for the reference human genome mapping, target identification and biomarker discovery at Celera Genomics, Roche Diagnostics and the Broad Institute of MIT and Harvard. At the Broad, he served as the Director of genome annotation where he led development and application of genome analysis pipelines for multiple high-profile genome projects. He was a key member of the early jumpstart phase of the Human Microbiome Reference Consortium. Earlier in his career, he did experimental and computational research at the National Center for Genome Resources (Santa Fe, New Mexico) and Sealy Center for Molecular Science.

Robert DeVita, MS PhD

Robert DeVita, MS, PhD is a Professor at the Icahn School of Medicine at Mount Sinai, in the Department of Pharmacological Sciences. He also serves as Director of the Medicinal Chemistry Core of the Drug Discovery Institute (DDI) at Mt Sinai, and is on the SAB of Circumvent, as well as being a co-founder of Attenua, Inc, and advisor for Mitokinin, Inc. Dr. DeVita has over 25 years of experience in the biopharmaceutical industry, including at Merck Research Laboratories as director of medicinal chemistry. His work spans the drug discovery paradigm from target identification through clinical stage development, and the identification of multiple development candidates including two Phase II clinical compounds for CNS and CV targets. Dr. DeVita also has experience in the discovery and development of PET imaging agents and translational biomarkers for CNS targets. He has developed, in collaboration with cross-disciplinary teams, orally active, brain penetrant, peripheral and GI tract drug targeting strategies. His R&D background across a range of therapeutic areas includes Oncology, CNS, pain, inflammation, diabetes, cardiovascular, hypertension, obesity, urology, and endocrinology.